BACKGROUND: Biological and technical variability has been increasingly appreciated as a key factor impacting red blood cell (RBC) storability and, potentially, transfusion outcomes. Here, we performed metabolomics analyses to investigate the impact of factors other than storage duration on the metabolic phenotypes of stored RBC in a multicenter study.
RESULTS:
Unsupervised analyses of metabolomics data from 599 selected samples revealed a strong impact (14.2% of variance) of storage duration on metabolic phenotypes of RBCs. The blood center collecting and processing the units explained an additional 12.2% of the total variance, a difference primarily attributable to the storage additive (additive solution 1 vs. additive solution 3) used in the different hubs. Samples stored in mannitol-free/ citrate-loaded AS-3 were characterized by elevated levels of high-energy compounds, improved glycolysis, and glutathione homeostasis. Increased methionine metabolism and activation of the transsulfuration pathway was noted in samples processed in the center using additive solution 1.
CONCLUSION: Blood processing impacts the metabolic heterogeneity of stored RBCs from the largest multicenter metabolomics study in transfusion medicine to date. Studies are needed to understand if these metabolic differences influenced by processing/storage strategies impact the effectiveness of transfusions clinically. Medicine; LR = leukoreduced; PCA = principal component analysis patients needing acute or chronic intervention. Massively or chronically transfused recipient categories include patients suffering from traumatic injuries (with or without hemorrhagic shock), cardiovascular disease (e.g., perioperative bleeding during cardiac surgery), or cancer patients undergoing chemotherapy/radiotherapy. Storage in the blood bank makes it possible to logistically handle both constant and sudden demands of RBCs and other blood products for rapid transfusion.
Refrigerated liquid storage of RBCs in blood banks has improved over the past approximately 100 years to achieve the current high standard of practice. 1 However, cold liquid preservation of packed RBCs is a nonphysiological process that exposes erythrocytes to low temperatures and storage solutions loaded with supraphysiological concentrations of additives (e.g., glucose, phosphates, and either mannitol or citrate in additive solution (AS)-1 and AS-3, respectively). 2 As a result, RBC storage induces a series of biochemical and morphological alterations collectively referred to as the storage lesion(s), 3 a phenomenon that ultimately compromises the cells' capacity to generate high-energy phosphate compounds (such as adenosine triphosphate [ATP] ) and cope with oxidative stress.
Ten years ago, a provocative series of retrospective studies suggested that the storage lesion(s) may negatively impact transfusion outcomes in certain categories of recipients. 4 Since then, omics technologies have helped to elucidate the complexity of the storage lesion, especially through the use of metabolomics, which provides a comprehensive overview of RBC metabolism. 5 While limited in the number of biological replicates and conditions tested in a single study, metabolomics investigations have flooded the literature over the past few years in an attempt to document the effect of different storage additives (SAGM, AS-1, AS-3, AS-5, AS-7, PAGGSM, PAG3M, ESOL-5), [6] [7] [8] [9] [10] [11] [12] [13] with adenine, alternative sugars, or antioxidants). [21] [22] [23] Tracing experiments have provided insights into fluxes through key antioxidant pathways 15 41 The apparent disconnect between studies could possibly in part be explained by the role that biological variability (of both donors and recipients) and processing strategies play on the development of the storage lesion and clinical outcomes. 42 To investigate the impact of donor demographic and genetic variability on metabolic phenotypes of stored RBCs in a large prospective cohort, four blood collection centers involved in the REDS-III RBC-Omics Study enrolled approximately 14,000 donors of different race-ethnicities, sex, and age to determine how donor biology impacts spontaneous and stress-induced hemolysis of RBCs in vitro after 42 days of storage. 43 Donors whose RBCs were at the extreme end of storage hemolytic phenotypes were recalled for a second donation, from which RBCs were manufactured according to standard operational procedures at each blood center and then stored under routine blood bank conditions and sampled at storage days 10, 23, and 42 to test for spontaneous, oxidative, osmotic, and mechanical hemolysis in vitro. Metabolomics analysis was performed on a total of 599 samples from 250 recalled donors. As a result, we are reporting the outcome of the largest to date multicenter metabolomics study of RBC stored under blood bank conditions. Results confirm and expand on the previous observations about the progressive accumulation of RBC metabolic changes during storage. While evaluation of the impact of donor biology (age, sex, ethnicity) and correlations of metabolomic findings with hemolytic phenotypes is beyond the scope of this preliminary analysis, here we report a significant impact of RBC collection/processing strategies associated with the hubs where the units were processed and stored, a phenomenon primarily explained by differences in storage additives. In light of these results, we comment on the need for physiological studies and in vivo RBC transfusion outcome analyses that evaluate the effectiveness and safety of blood units while taking into account differences in processing methods and additive solutions.
MATERIALS AND METHODS

REDS-III RBC-Omics
Donor selection criteria and recruitment procedures for RBC-Omics were previously described by Kanias et al. 43 Donors were enrolled at the American Red Cross (ARC; Farmington, CT), 
Sample processing and metabolite extraction
Commercial reagents were purchased from Sigma-Aldrich unless otherwise noted. An isotopically labeled internal standard mixture including a mix of 13 C 15 N-labeled amino acid standards (2.5 μM) was prepared in methanol. 30 RBCs
were separated by centrifugation (10 min at 4 C and 2500g), then 100 μL was mixed with water and the mixture of isotopically labeled internal standards (1:1:1, vol/vol/vol). 30 The samples were extracted with methanol (final concentration of 80% methanol). After incubation at −20 C for 1 hour, the supernatants were separated by centrifugation and stored at −80 C until analysis.
5,24
Ultra-high-performance liquid chromatographymass spectrometry metabolomics
Analyses were performed using a Vanquish ultra-highperformance liquid chromatography coupled online to a mass spectrometer (Q Exactive, Thermo Fisher). Samples were analyzed using a 3-minute isocratic condition 44 or a 9-minute gradient as described. 24 Solvents were supplemented with 0.1% formic acid for positive mode runs and 1 mM ammonium acetate for negative mode runs. Mass spectrometry acquisition, data analysis, and elaboration were performed as described. 24 
RESULTS
From blinded to unblinded through unsupervised analyses
Metabolomics analyses were performed on 599 frozen RBC samples processed on Day 10, 23, or 42 of storage from LR-RBC units collected from 250 recalled RBC-Omics donors at four different blood centers in the United States (Figs. 1A and 1B). Metabolomics workflow and procedures were extensively described and reviewed (Fig. S1 , available as supporting information in the online version of this paper). 5 Sample identifiers for snap-frozen aliquots selected for metabolomics analysis were blinded and randomized by the REDS-III central laboratory (BSRI) prior to shipping to Bloodworks Northwest in Seattle, Washington, where the samples were extracted and the extracts sent to the University of Colorado Denver by overnight shipping on dry ice. Upon arrival in Denver, samples were randomized a second time prior to analysis via ultra-high-performance liquid chromatography-mass spectrometry. Unsupervised hierarchical clustering analyses (HCAs) and PCAs were performed on targeted and untargeted metabolomics results generated in Denver (Figs. 1C and 2A , Figs. S2 and S3, available as supporting information in the online version of this paper). HCA identified three main clusters: compounds informing this discrimination are highlighted in Fig. S2 and include metabolites involved in energy homeostasis (ATP, adenosine diphosphate [ADP], ADP-ribose, glucose, fructose bisphosphate, etc.), carboxylates (citrate, oxaloacetate), and metabolic markers of the age of blood (lactate, hypoxanthine, 5-oxoproline). 25 Based on the latter group of metabolites (for which absolute quantities were determined against stable isotope labeled internal standards; Fig. S3 ), we predicted that the three main clusters grouped samples on the basis of storage day (Fig. 2B) . A total of 242, 180, and 177 samples were predicted as samples at Storage Days 10, 23, and 42, respectively (Fig. 1C) . Once unblinded, we noted that only 8 samples were misclassified in the Day 23 group and one in the Day 42 group, for a total of 590 correct predictions of 599 samples (98.5% accuracy; Fig. 2B ).
In addition to the identification of three main clusters, subclusters including 102 and 54 samples were noted at Days 10 and 23 (Fig. 1C) . This phenomenon was even more evident in HCA graphs of the results from unsupervised analyses (based on approximately 200,000 features), clearly showing an impact of factors other than storage time on more than 40% of the total features monitored in this study (Fig. S3) . Although PCA clearly revealed a significant effect of storage time on metabolic phenotypes of stored RBCs, explaining 14.5% of the total variance across PC1 ( Fig. 2A) , an additional 12.2% of variance was explained by PC2, which was apparently affected by factors other than storage duration (Fig. 2B) . Once unblinded to information about donors and day of RBC storage, partial least squares discriminant analyses revealed that PC2 explained 10.5% of the total variance, suggesting that factors other than storage duration alone (9.1% of the variance) impacted the metabolic phenotypes of the samples tested here (Fig. 1D shows a threedimensional representation, while Fig. 2B illustrates the interactions of the top five PCs on two-dimensional projections).
Metabolic markers of the RBC storage age-revisited
While limited in the number of time points tested, the present study offers a unique opportunity to expand our understanding of the metabolic effects of RBC storage. Trends observed here are consistent with previous studies [6] [7] [8] [9] [10] [11] [12] [13] 24 and identified increases with prolonged storage time in hypoxanthine (lowest false discovery rate-corrected p value: 1.21 e-217 of increasing metabolites), 5-oxoproline, lactate, homocysteine and hydroxisourate and decreases in methionine (lowest false discovery rate-corrected p value: 1.52 e-75 of decreasing metabolites), glutamine, ATP, adenine, and 2,3-diphosphoglycerate as the most significant metabolic changes by ANOVA (Fig. 3A) , with >100 metabolites showing false discovery rate-corrected p values less than 7 e-05 (Table S1 , available as supporting information in the online version of this paper). A series of fatty acids and oxylipins (including eicosapentaenoic acid, icosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, eicostatraenoic acid, and icosatrieonoic acid) all increased significantly over storage duration and made it to the top 50 significant metabolites by ANOVA (Fig. 3B ). Of note, relative and absolute quantitative measurements for metabolites including 5-oxoproline, methionine, lactate, glutathione glutamine, fructose bisphosphate, glucose, 2,3-diphosphoglycerate clustered together in the HCA in Fig. 3B , further strengthening the significance of the observation and providing reassurance of the reliability of relative quantitative measurements.
Processing hub identified as a main factor impacting metabolic heterogeneity of REDS III RBCOmics samples
In an attempt to identify the main factors informing the discrimination of REDS III RBC-Omics samples across PC2 in PCA (Fig. S5A , available as supporting information in the online version of this paper, provides a three-dimensional representation), samples were classified on the basis of the storage day and the hub that processed the units, and the statistical analyses repeated as a two-factor (time series + hub) analysis via MetaboAnalyst. Of note, PCA revealed a clear effect of processing hub on RBC metabolic heterogeneity (Fig. 4A) . ANOVA revealed that the top factor contributing to this clustering was the storage additive used in each hub (AS-3 at ARC, BSRI, and ITxM; AS-1 at BCW). Metabolites like citrate and diphosphates (higher in AS-3) or mannitol (absent in AS-3) were identified as key discriminant metabolites across groups (to present results in a readable format, Fig. 4B and subsequent figures show line plots for 25 representative samples in each group). HCA of metabolic phenotypes based on the combined effect of storage day, hub, and storage additives clearly shows that metabolic heterogeneity was attributable to AS-1 (Fig. 4C) . AS composition promoted stark differences across hubs in the levels of several metabolites involved in purine metabolism/oxidation (Fig. 4D) , glycolysis and carboxylate metabolism (Fig. 5 ), glutathione and sulfur homeostasis (Fig. 6 ), citrate metabolism (Fig. 7) , and fatty acid/signaling lipid homeostasis (Fig. S5B ).
Metabolic pathways impacted as function of processing hubs
Metabolomics analyses revealed a center-dependent impact on purine oxidation-partly explained by the formulation of 
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storage additives-with decreased levels of ATP, ADP, IMP and increased levels of adenosine and purine oxidation byproduct urate (but not hydroxyisourate) in samples stored in AS-1 (Fig. 4D) . No significant differences in the levels of hypoxanthine were noted across hubs ( Supplementary  Fig. 5 ). This observation is in part explained by decreased glucose and hexose phosphate and fructose bisphosphate levels in the same subset of samples stored in AS-1, which were, however, characterized by higher levels of late trioses and triose phosphates (glyceraldehyde 3-phosphate and lactate; Fig. 5 ), suggestive of heterogeneity in glycolytic phenotypes across samples. The same AS-1 group of samples was characterized by significantly lower levels of glutamine; gamma-glutamyl-cysteine (a precursor to glutathione); dehydroascorbate and lactoyl-glutathione; and higher levels of 5-oxoproline, S-adenosyl-methionine, and S-adenosyl-homocysteine-suggestive of a differentially regulated glutathione homeostasis and transsulfuration pathway in this group in comparison to blood processed at other hubs (Fig. 6 ). AS-1-stored RBCs showed significantly lower levels of free fatty acids, pyruvoyl-tetrahydropterin (a guanosine metabolism product) and the highest levels of sphingosine 1-phosphate (Fig. S5) . Samples processed at ITxM-which had leukoreduction performed several days after collection, whereas the other three hubs performed prestorage leukoreduction-had the highest levels of the sulfur-containing compound taurine and the short odd-chain fatty acids heptanoic acid (used to ease the formation of methyl-ester in the industrial processes that generate phthalates 45 ) and 9-oxonanoic acid (a common water-soluble ketoacid 46 ; Fig. S5 ). Finally, since mannitol-free AS-3 is loaded with citrate, we focused on carboxylate metabolism 13, 16, 24 in RBCs from different hubs. Samples stored in AS-1 were characterized by lower levels of citrate (absolute and relative quant graphs are shown in Figs. 4B and 7, respectively), oxaloacetate, homoaconitate, and acyl-carnitine C6-DC (Fig. 7) . The same samples were instead characterized by higher levels of malate and fumarate, by-products of reactions preserving nicotinamide adenine dinucleotide homeostasis and purine salvage in the presence of aspartate (an almost completely inactive pathway in RBCs
31
).
DISCUSSION
In this study, we report observations from an extensive metabolomics analysis of stored packed RBCs (599 samples tested from 250 recalled RBC-Omics donors) from four different centers across the United States. First, previously reported markers of the metabolic age of stored RBCs 25 were confirmed. Second, additional markers were identified with methionine and sulfur metabolism (specifically S-adenosyl-methionine and S-adenosyl-homocysteine) emerging as significant variables informing storage time and ASspecific clustering. Although this and other studies have pointed out the potential relevance of storage-induced methionine consumption and activation of the transsulfuration pathway in relation to purine homeostasis and polyamine synthesis, 8, 21, 24 further studies will be necessary to mechanistically assess the relevance of this pathway. Most importantly, we noted a substantial metabolic heterogeneity across blood centers using different storage additives and/or processing workflows. In particular, PCA clearly revealed that these factors are as impactful as storage duration with respect to metabolic heterogeneity. This observation is relevant in the light of the increased awareness about the role of biological/processing variability across transfused units and their potential impact on transfusion outcomes. 42 Pathways affected by storage additives were consistent with previous reports on the metabolic differences between AS-1 and AS-3 in paired 13 or independent studies. 8,9,24 AS-3 is mannitol free and is loaded with citrate to compensate for osmolarity. Citrate is a carboxylic acid that can be metabolized by RBCs despite their lack of mitochondria. 13, 16, 24, 47 Metabolism of citrate into malate, lactate, and oxaloacetate has been extensively documented through metabolic tracing with deuterated or 13 C tracers 13, 16, 24, 47 ; our study suggests a role for citrate metabolism in fueling homoaconitate via ketoglutarate and homocitrate intermediates. Sphingosine 1-phosphate plays a key role in RBC responses to hypoxia. 48 Previous studies have reported storage-induced decreases in sphingosine 1-phosphate, 24, 49 a finding here recapitulated in all tested samples except from those coming from units stored in AS-1. Altered energy metabolism was noted in units processed in the hub using AS-1, as inferred from lower levels of high-energy phosphate compounds (including ATP and ADP) and differential levels of hexose and triose (phosphate) compounds. Because energy homeostasis is intertwined with redox homeostasis (e.g., glutathione synthesis is an ATP-dependent process), it is interesting to note an impairment of glutathione homeostasis and sulfur metabolism (especially methionine catabolism) in the very same group of samples that show dysregulated energy homeostasis.
Previous smaller scale (in comparison to RBC-Omics) controlled studies on twins have shown a donor dependency of energy and redox homeostasis. 27, 28 Our larger study shows that these same metabolic pathways are significantly impacted by the formulation of storage additives in a manner that goes beyond the direct impact of the unique components in the AS (e.g., mannitol vs. citrate in AS-1 vs. AS-3). Appreciation of the influence of processing and storage additives on the metabolic heterogeneity of stored RBCs in a multicenter study of this scale raises the possibility that this and other manufacturing variations may confound results from randomized clinical trials addressing, for example, the clinical impact of days of in vitro RBC storage. Metabolites deriving from processing workflows (e.g., oddchain fatty acids and dicarboxylates derived from industrial processes to generate methyl esters for the production of phthalates) were here associated with specific hubs, suggesting that even industrially controlled processes such as the production of storage bag plasticizers may inadvertently impact the final heterogeneity of the manufactured RBC (which, again, does not necessarily imply an impact on its safety and efficacy). A limitation of this study is that it did not address the impact of other variables (e.g., donor sex, age, ethnicity, and prior donation frequency) that are recognized to correlate with hemolysis. 43, 50 Future studies will address the correlations of the present findings with those variables, as well as the propensity to hemolyze in several in vitro hemolytic assays and with donor genetics. Analyses are also planned to determine the in vivo consequences of these findings following transfusions of RBC components from RBC-Omics donors into recipients represented in the REDS-III linked donor-recipient database.
CONCLUSION
In this manuscript, we report a data-driven analysis of metabolomics results from stored RBC samples from the REDS-III RBC-Omics study. A total of 599 samples generated from 250 donors in four different blood centers were processed and analyzed, making this the largest multicenter metabolomics study of stored RBCs to date.
Unsupervised analyses of metabolomics data revealed that hub/processing/additives significantly impact the metabolic heterogeneity of stored RBCs, to an extent comparable to storage duration. Pathways impacted by hub/processing/ additives included glycolysis, purine (including ATP) and glutathione homeostasis, and carboxylate and sulfur metabolism; these pathways have been previously shown to depend on the storage age and donor variability. Appreciation of the metabolic heterogeneity of stored RBCs and the relevance of processing strategies/additives does not necessarily imply any impact on transfusion outcomes. Future studies will be necessary to investigate whether variables such as processing/storage additives may have masked the impact of age of blood on transfusion outcomes in recent randomized clinical trials. This study further stresses the opportunity to further improve standardization of blood product processing 42 and the formulation of storage additives. Finally, this study demonstrates the relevance of metabolomics technologies in transfusion medicine and the potential transformative impact that data generated through this technology can have when correlated with transfusion outcomes, as recommended by recent meetings on the state of science in transfusion medicine sponsored by the National Heart, Lung, and Blood Institute and the Food and Drug Administration. 
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